Summary

Report Overview
Global Erectile Dysfunction Drugs Market reached US$ 3.5 billion in 2023 and is expected to reach US$ 5.0 billion by 2031, growing at a CAGR of 4.7% during the forecast period 2024-2031.
Erectile dysfunction (ED) is a common condition affecting men of all ages, particularly older individuals. It can be caused by physical and psychological factors, such as cardiovascular disease, diabetes, obesity, hormonal imbalances, stress, anxiety, and depression. Lifestyle choices like smoking, excessive alcohol consumption, and lack of exercise can also contribute to ED.
Market Dynamics: Drivers & Restraints
Increasing prevalence of erectile dysfunction
ED is a condition where men struggle to maintain a penile erection due to physical and psychological issues like diabetes, high cholesterol, smoking, stress, and mental health.
For instance, according to World Health Organization (WHO) reports that 15% of men are affected by endometriosis (ED) each year, with a projected 320 billion cases by 2025. ED is particularly prevalent in geriatric men due to a natural decline in testosterone levels, reduced blood flow, and age-related physiological changes. The geriatric population is more likely to have chronic conditions like diabetes, cardiovascular disease, and hypertension, which are major risk factors for ED. The World Social Report 2023 predicts a global population of 1.6 billion by 2050, further increasing the prevalence of ED in men.
Challenges associated with the drugs
The global erectile dysfunction drugs market faces several challenges, including the availability of generic versions, stigma associated with the condition, potential side effects, and the rise of alternative therapies like herbal remedies and lifestyle changes. These factors can hinder the market's growth, leading to increased competition and reduced drug prices. 
Additionally, the stigma associated with the condition can discourage men from seeking treatment, leading to underreporting and underdiagnosis. Therefore, these factors collectively pose a significant challenge to the global erectile dysfunction drugs market.
Market Segment Analysis
The global erectile dysfunction drugs market is segmented based on drug class, route of administration, distribution channel, and region.
The PDE5 Inhibitors from the drug class segment accounted for approximately 41.3% of the erectile dysfunction drugs  market share
The PDE5 inhibitors from the drug class segment accounted for approximately 41.3%. Phosphodiesterase type 5 (PDE5) inhibitors, such as Viagra, Cialis, and Levitra, are the most commonly prescribed treatments for erectile dysfunction (ED) due to their proven efficacy and safety. 
These drugs enhance blood flow to the penis, facilitating an erection in response to sexual stimulation. Their widespread adoption is driven by strong clinical evidence, ease of oral administration, and favorable patient outcomes. The availability of both branded and generic versions has made them more accessible. Despite competition from newer treatments, PDE5 inhibitors remain the cornerstone of ED management worldwide.
For instance, in June 2024, Palatin Technologies, a biopharmaceutical company, initiated a Phase 2 clinical study for erectile dysfunction treatment using bremelanotide (BMT), a melanocortin 4 receptor co-administered with a phosphodiesterase 5 inhibitor (PDE5i).
Market Geographical Analysis
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to novel drug approvals, advancements in medical technology have led to more effective and convenient treatment options, encouraging more individuals to seek treatment and expanding the market for ED drugs.
For instance, in February 2024, Petros Pharmaceuticals and 23andMe partnered with a major AI software provider to integrate advanced technology into its Self-Selection Study for STENDRA (avanafil) OTC approval. The AI-driven tool aimed to improve screening accuracy, ensure safe access to medication under FDA & ACNU guidelines, and enhance Petros' pathway toward OTC status.
Moreover, in June 2023, the FDA approved the over-the-counter sale of MED3000 (Eroxon), a topical gel that treats ED and may work faster than regular ED medication. The gel comes in a single-use tube.
Market Segmentation
By Drug Class
PDE5 Inhibitors
Testosterone Replacement Therapy
Alprostadil
Combination Drugs
By Route of Administration
Oral
Injectable
Topical
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
The U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the market include Pfizer Inc., Eli Lilly and Company, Bayer AG, GlaxoSmithKline plc, Johnson & Johnson, Therapeutics MD, Inc., VIVUS, Inc., Menarini Group, MediSprout, Astellas Pharma Inc among others.
Key Developments
In May 2023, Hims & Hers Health, Inc. launched Hard Mints, chewable mint-flavored tablets for treating sexual dysfunction, in the U.S. They will be available in the UK starting in June. Leveraging active ingredients such as Viagra, Cialis, & Levitra, they aim to offer a personalized and discreet solution backed by positive customer feedback and facilitated through their telehealth platform.
Why Purchase the Report?
To visualize the global erectile dysfunction drugs market segmentation based on drug class, route of administration, distribution channel, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development. 
Excel data sheet with numerous data points of the erectile dysfunction drugs market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global erectile dysfunction drugs market report would provide approximately 64 tables, 61 figures, and 186 pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in prevalence of erectile dysfunction
4.1.1.2. Novel approach for new drugs
4.1.2. Restraints
4.1.2.1. Challenges associated with the drugs
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Drug Class
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
6.1.2. Market Attractiveness Index, By Drug Class
6.2. PDE5 Inhibitors*
6.2.1. Introduction
6.3. Testosterone Replacement Therapy
6.4. Alprostadil
6.5. Combination Drugs
7. By Route of Administration
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.2. Market Attractiveness Index, By Route of Administration
7.3. Oral*
7.3.1. Introduction
7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.4. Injectable
7.5. Topical
7.6. Others
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Pfizer Inc*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Eli Lilly and Company
11.3. Bayer AG
11.4. GlaxoSmithKline plc
11.5. Johnson & Johnson
11.6. Therapeutics MD, Inc
11.7. VIVUS, Inc.
11.8. Menarini Group
11.9. MediSprout
11.10. Astellas Pharma Inc (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us